Navigation Links
Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
Date:11/7/2011

lease may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the quarter ended September 30, 2011, and other regulatory filings from time to time. There can be no
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The leading companies ... billion global cardiac rhythm management device market dominate ... that Medtronic, St. Jude Medical, Boston Scientific and ... this market segment. The healthcare market research publisher,s ... uses 2015 as a base year, providing forecasts ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... protection, repair and regeneration, today announced that J.J. ... to present a corporate overview at two upcoming investor ... the SeeThruEquity 4 th Annual Microcap Conference on ... City at 11:00 am EDT.  A webcast ...
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, 2015 ... CSL Behring its 2015 Corporate Leadership Award as ... science and improving the care of the bleeding disorders community.  ... and Managing Director, CSL Limited, during the NHF Annual Spring ... May 21. "The National Hemophilia Foundation is dedicated ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4
... Novel Biomarkers Displaying 90% Sensitivity in Breast ... ... announced today the,discovery and validation of the most frequent DNA alterations detected ... appeared in PLoS ONE. The study entitled, "Identification of,Novel High-Frequency DNA Methylation ...
... GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX), an Atlanta-based ... has retained Financial,Relations Board (FRB), as its Investor ... HIV-1/AIDS vaccine human trial results need to be,conveyed ... AIDS,pandemic," stated Kathy Waller, co-president of FRB., ...
Cached Medicine Technology:Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers 2GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 2GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 3GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 4
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
(Date:5/22/2015)... “It’s like learning an new ... Vice President of Clinical Operations/Education and Training at ... impacts how care is coded and reimbursed.” , ... care reimbursement, operations and compliance consulting, as well ... launches a new series of day-long seminars on ...
(Date:5/22/2015)... Carnegie Science Center and ... partnership to develop BodyTech, a dynamic, three-pronged health and ... a new exhibit at the Science Center called BodyWorks, ... new traveling science show, Anatomy Adventure, which will hit ... Designed to explore a wide range of topics surrounding ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the beginning ... some tips to help promote safe travel. , According to ... traffic fatalities this Memorial Day weekend. Amica is sharing the ... Association: , , Always wear a ... seatbelt, whether they’re driving or riding along as a passenger. ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship of ... is in his second year of racing in the professional ... Fire Department in Missoula, MT. He entered the triathlon scene ... career, he has had 15 1st Place finishes. In his ... in all seven of his 2014 races, including two 2nd ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
... Poor sleep tied to quality of life, depression, study says ... common among elderly people who live in assisted living facilities, ... associated with declining quality of life and increased depression. , ... when they,re no longer able to live independently but do ...
... while longer-term risks are uncertain , FRIDAY, May 7 ... Gulf of Mexico and now some barrier islands off ... environment while posing risks to public health, experts say. ... headaches, nausea, coughing and throat irritation, according to the ...
... from a corticosteroid regimen have fewer cardiovascular events ... survival rates and reducing early mortality, according to ... of Cincinnati (UC) transplantation researchers. Researchers with ... medicine are presenting the work at the American ...
... explain different outcomes for women with similar-looking tumors, expert ... of breast cancer into subtypes can be achieved through ... U.S. researchers say. , They analyzed 32 gene expression ... and six classification models. , "We studied these models ...
... breast cancer , C.B. Agborsangaya, FINLAND, As women ... the incidence of pregnancy-associated breast cancer is expected ... p53 autoantibody-positive pregnant women may be useful in ... cancer. Abstract 92P: Post traumatic stress disorder ...
... a benign tumor of mesenchymal origin which is mostly ... 2/3 of small bowel occlusion caused by up to ... frequent benign tumor that causes invagination in its submucous ... form. However, multiple lipomas within the intestinal duplication canal ...
Cached Medicine News:Health News:Sleepless Nights Plague Assisted Living Residents 2Health News:Gulf Oil Spill Could Threaten Human Health 2Health News:Gulf Oil Spill Could Threaten Human Health 3Health News:Study finds post-transplant patients off steroids have fewer cardiovascular events 2Health News:Study finds post-transplant patients off steroids have fewer cardiovascular events 3Health News:Simple Test May Identify Breast Cancer Subtypes 2Health News:Interesting stories at the IMPAKT Breast Cancer Conference 2Health News:Interesting stories at the IMPAKT Breast Cancer Conference 3
... its synthetic bone substitute Ossatura. Developed at Isotis, ... material, i.e. a material that is designed to ... the musculo-skeletal system that results in bone growth. ... and reduces in part or entirely the need ...
Schuknecht-Weitlaner retractor, sharp, angled arms....
Beckman-Weitlaner retractor, blunt, with hinged arms, 6 1/2"....
Daubenspeck sharp curette, 8....
Medicine Products: